Top-line data for two identical Phase III studies of faricimab, Roche Holding AG’s novel bispecific antibody product for retinal diseases, suggest it is no better than Bayer AG’s Eylea but still likely to prove a thorn in the side of Novartis AG’s newcomer Beovu.
Roche’s Ophthalmic Bi-Specific Faricimab Still A DME Contender
Data In Wet AMD Still Awaited
Initial data show non-inferiority to Eylea in diabetic macular edema with reduced frequency dosing but not superiority. Even so, market dynamics suggest it could still carve out blockbuster sales.
